Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
ADNOC Gas Targets Up to $4B Profit in 2026 
CAMBRIDGE, Mass., Feb. 22, 2018 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter and full-year 2017 financial results, business highlights and 2018 financial guidance.
| What: | Vericel Corporation Fourth-Quarter 2017 Earnings Call | |
| When: | Monday, March 5, 2018 at 8:30am (EST) | |
| Where: | http://investors.vcel.com/events-presentations | |
| How: | The conference call will be available live in the Investors section of the Vericel website at http://investors.vcel.com/events-presentations. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary. |
To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation fourth-quarter 2017 earnings call. If calling from outside the U.S., please use the international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast will be available at http://investors.vcel.com/events-presentations until March 5, 2019. A replay of the call will also be available until 11:30am (EST) on March 10, 2018 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 4899311.
About Vericel Corporation
Vericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. Vericel is marketing MACI® (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Vericel is also marketing Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2018 Vericel Corporation. All rights reserved.
Global Media Contacts:
David Schull
Russo Partners LLC
+1 212-845-4271 (office)
+1 858-717-2310 (mobile)
[email protected]
Karen Chase
Russo Partners LLC
+1 646-942-5627 (office)
+1 917-547-0434 (mobile)
[email protected]
Investor Contacts:
Chad Rubin
The Trout Group
[email protected]
+1 (646) 378-2947
Lee Stern
The Trout Group
[email protected]
+1 (646) 378-2922
